Supplementary Tables 1-5, Supplementary Figures 1-6 from Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α

Abstract

<p>Table S1: Detailed cell line information; Table S2: Reagent details; Table S3: p values from proliferation assays presented in Supplemental Fig. 3 and Supplemental Fig. 4; Table S4: Tumor volume summary for pediatric rhabdoid tumor and osteosarcoma xenografts; Table S5: Characterization of patient-derived xenograft models for PDGF receptor and ligand expression; Figure S1. PDGF receptor expression in pediatric bone and soft tissue tumors cell lines; Figure S2. Olaratumab blocks PDGFRα activation in normal human fibroblasts; Figure 3. The AT/RT cell lines BT-12 and BT-16 are negative for PDGF receptor expression and are not affected by olaratumab treatment; Figure 4. Olaratumab reduces PDGFRα-expressing tumor cell proliferation alone and in combination with chemotherapy; Figure 5: Supplemental Figure 5. Olaratumab serum concentration is consistent across different mouse models of pediatric bone and soft tissue sarcoma; Figure 6. Characterization of CCSARC005 osteosarcoma patient-derived xenograft model for PDGFRα expression; Figure 5. Olaratumab serum concentration is consistent across different mouse models of pediatric bone and soft tissue sarcoma; Figure 6. Characterization of CCSARC005 osteosarcoma patient-derived xenograft model for PDGFRα expression.</p>